The small scale bioreactors market is estimated to grow from USD 2,479 million in 2025 to reach USD 2,739 million in 2026 and USD 5,796 million by 2035, representing a CAGR of 8.68% during the forecast period 2026 to 2035. In 2025, the batch / fed batch mode of operation dominated the market and is estimated to hold 90% of the overall revenue share by 2035. Fed batch bioreactors provide controlled nutrient environment, preventing accumulation of inhibitory byproducts that can limit cell growth....

The global nanoparticle formulation market, valued at USD 6.2 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 15.2 billion by 2035, with a CAGR of 9.3% during the forecast period 2026 to 2035. In June 2026, CEPI announced up to $9.7 million in additional funding to POP Biotechnologies to advance its SNAP nanoparticle-based vaccine platform into Phase 1 trials. The program targets rapid-response vaccines for epidemic threats such as H5N1 and Disease X, aiming to improve ant...

The global iPSC-derived cell therapy market is expected to rise from USD 1.52 billion in 2026 to reach USD 9.79 billion by 2040, growing at a CAGR of 14.2% over the forecast period 2026 to 2040, driven by clinical translation and scalable allogeneic platforms. Through 2040, the market will remain high-growth as gene-edited immune-evasive therapies gain share and reduce immunosuppression dependence. Pancreatic islet cells, cell engineering, and contract development services will outpace establish...

The stem cell therapy market, valued at USD 204 million in 2025, is projected to reach USD 321 million in 2026 and USD 1,290 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. Based on end users, hospitals dominate the overall market as they possess the specialized infrastructure and expertise required to administer advanced stem cell therapies. Across key geographical regions, North America captures the largest market share owing to substantial research fundi...

The global non-small cell lung cancer market size is estimated to grow from USD 23.8 billion in 2025 to USD 26.4 billion in 2026 and USD 56.0 billion by 2035, representing a CAGR of 8.7% during the forecast period. It is worth highlighting that among all the forms of non-small cell lung cancer, squamous cell carcinoma is one of the most common types and it may develop due to prolonged use of tobacco. In fact, the World Health Organization report shows that smoking is the main cause of lung cance...

The small molecule API manufacturing market, valued at USD 197 billion in 2025, is projected to reach USD 204 billion in 2026 and USD 266 billion by 2035, representing a CAGR of 3.0% during the forecast period 2026 to 2035. In terms of type of manufacturers, the in-house manufacturers are likely to secure ~65% of the overall revenue share in 2026, due to the growing preference towards large, vertically integrated pharmaceutical companies. In March 2026, Cambrex announced the initial completion o...

The global cell encapsulation market, valued at USD 5.0 billion in 2025, is projected to reach USD 5.7 billion in 2026 and USD 15.8 billion by 2035, representing a CAGR of 12.0% during the forecast period 2026 to 2035. In April 2026, Atelerix signed a strategic partnership agreement with JH Health to expand the distribution and use of its proprietary non-cryogenic hydrogel encapsulation and cell preservation technology in the Middle East. In March 2026, researchers at MIT published findings on a...

The global viral vector and plasmid DNA manufacturing market, valued at USD 843 million in 2025, is projected to reach USD 937 million in 2026 and USD 2,161 million by 2035, with a CAGR of 9.73% during the forecast period 2026 to 2035. Presently, over 300 industry and non-industry players across the globe are actively involved so as to support the expanding pipeline of cell therapies, gene therapies, and vector-based vaccines, as per viral vectors and plasmid DNA manufacturing market report. In...

The global live cell encapsulation market, valued at USD 613 million in 2025, is projected to reach USD 642 million in 2026 and USD 1,787 million by 2035, representing a CAGR of 12.1% during the forecast period 2026 to 2035. In terms of therapeutic area, metabolic disorders are likely to hold the highest share (over 40%) of the future market share. Based on the type of payment, upfront payments capture the largest share (over 85%) of the current market. In terms of geographical regions, North Am...

The global non-viral transfection reagents market, valued at USD 0.79 billion in 2025, is projected to reach USD 0.89 billion in 2026 and USD 2.01 billion by 2035, representing a CAGR of 9.5% during the forecast period 2026 to 2035. In October 2025, MaxCyte signed a platform licensing agreement with Moonlight Bio, granting non-exclusive research, clinical, and commercial rights to Moonlight Bio’s Flow Electroporation technology and ExPERT platform for scalable development and manufacturing of...

The global biologics API market size, valued at USD 70.4 billion in 2025, is projected to reach USD 78.4 billion in 2026 and USD 153.8 billion by 2035, representing a CAGR of 8% during the forecast period, 2026 to 2035. Several large biopharmaceutical players, such as Novartis, Pfizer, Roche and Eli Lilly are supporting the active pharmaceutical ingredient manufacturing in their in-house API manufacturing facilities for the efficient production of various biologics. In the future, hybrid manufac...

The global fill finish pharmaceutical contract manufacturing market size, valued at USD 7.5 billion in 2025, is projected to reach USD 7.9 billion in 2026 and USD 12.1 billion by 2035, representing a CAGR of 4.8% during the forecast period 2026 to 2035. The market growth is driven by rising pharmaceutical outsourcing, increasing demand for complex injectable formulations, and expanding biologics pipelines. Growing investments in advanced manufacturing technologies and capacity expansion further...

The mRNA synthesis and manufacturing market is estimated to be USD 0.56 billion in 2026. It is expected to reach USD 4.20 billion by 2035, representing a CAGR of 40.9% between 2028 and 2035. In June 2025, Ethris entered into a collaboration with Thermo Fisher Scientific, combining the former company’s comprehensive mRNA technology platforms with Thermo Fisher’s manufacturing capabilities, with an aim to advance mRNA therapeutics from research to clinical stages. In 2025, commercial scale sub...

The targeted protein degradation market is estimated to grow from USD 0.48 billion in 2024 to reach USD 1.00 billion in 2025 and USD 6.94 billion by 2035, representing a higher CAGR of 21% during the forecast period. In June 2025, SEED Therapeutics announced the appointment of Dr. Bill Desmarais as the Chief Financial Officer and Chief Business Officer, who previously served as Chief Business Officer at Alchemab Therapeutics. In May 2025, Kesmalea Therapeutics appointed Tim Clackson to its board...

The global biotherapeutics market, valued at USD 481 billion in 2025, is projected to reach USD 528 billion in 2026 and USD 1,048 billion by 2035, with a 7.9% CAGR during the forecast period 2026 to 2035. Biotherapeutics industry is anticipated to witness upward trajectory owing to the growing shift towards biologics for treating wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. The recent USFDA accelerated approval of AbbVie's Emrelis™ (telisotuzumab ved...

The global veterinary regenerative medicine market size, valued at USD 388 Million in 2025, is projected to reach USD 437 Million in 2026 and USD 1,189 Million by 2035, representing a CAGR of 11.8% during the forecast period. In terms of product, stem cell therapies is securing 53% of the market share driven by the widespread adoption of these therapies to treat wounds, damages tissues and chronic conditions. With regards to end user, the veterinary hospitals / clinics segment holds the highest...

The global regenerative medicine for spinal cord market size, valued at USD 16 million in 2025, is projected to reach USD 54 million in 2026 and USD 655 million by 2035, representing a CAGR of 32% during the forecast period, 2026 to 2035. The growth in the market is driven by strong scientific progress, expanding clinical trial activity, and increasing investment in advanced therapies such as stem cells and gene-based approaches. The global market for regenerative medicine for spinal cord injuri...

Researchers are currently focusing on the development of advanced stem cells, platelet-rich plasma (PRP), monoclonal antibodies (mAb), nutritional supplements, and pain management medication to improve motor function and comfort. In July 2025, Gallant (US) announced USD 18 million funding support to bring the first USFDA approved ready-to-use stem cell therapy to veterinary medicine to improve mobility in pets.

The cell sorting market, valued at USD 903 million in 2025 is expected to reach USD 1,078 million in 2026 and USD 3,085 million by 2035, representing a higher CAGR of 12.4% during the forecast period 2026 to 2035. Currently, the consumables and isolation kits segment dominates the market with ~60% market share and is likely to grow at a relatively higher CAGR, during the forecast period.

The cell line development market size valued at USD 1.46 billion in 2025, is project to reach USD 1.69 billion in 2026 and USD 4.50 billion by 2035, representing a higher CAGR of 11.5% during the forecast period 2026 to 2035. In terms of source of cell line, mammalian cells segment dominates the market with a 74% revenue share due to their critical role in producing complex proteins, monoclonal antibodies, and cell- and gene-based therapies. Notably, mid-sized players lead the market with a 39%...